Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms

Biological Psychiatry

Volumn 41, Issue 3, 1997, Pages 377-380

  Von Moltke, Lisa L ^a   Duan, Su Xiang ^a   Greenblatt, David J ^a   Fogelman, Steven M ^a   Schmider, Jürgen ^a   Harmatz, Jerold S ^a   Shader, Richard I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

alprazolam; cytochrome P450 3A; drug interaction; SSRI; venlafaxine

Indexed keywords

ALPRAZOLAM; CYTOCHROME P450; DESVENLAFAXINE; DRUG METABOLITE; N DESMETHYLVENLAFAXINE; NORFLUOXETINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ARTICLE; DRUG METABOLISM; HUMAN; INHIBITION KINETICS; PRIORITY JOURNAL;

ALPRAZOLAM; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CYCLOHEXANOLS; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; GABA MODULATORS; HUMANS; ISOENZYMES; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING;

EID: 0031081611     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(96)00406-4     Document Type: Article

References (24)

1. Ball S, Ahern D, Kao J, Scatina J (1996): Venlafaxine (VF): Effects on CYP2D6 dependent imipramine (IMP) and desipramine (DMP) 2-hydroxylation; Comparative studies with fluoxetine (FLU) and effects on CYP1A2, CYP3A4 and CYP2C9. Clin Pharmacol Ther 59:171.
2. Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS (1995): Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 15:320-326.
3. Daniel DG, Randolph C, Jaskiw G, et al (1994): Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 14:340-343.
4. Ellingrod VL, Perry PJ (1995): Nefazodone: A new antidepressant. Am J Health Syst Pharmacol 52:799-812.
5. Fleishaker JC, Hulst LK (1994): A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 46:35-39.
6. Fogelman S, Schmider J, Greenblatt DJ, Shader RI (1995): Metabolism of venlafaxine: The role of P450 isoforms. J Clin Pharmacol 35:936.
7. Greenblatt DJ, Wright CE (1993): Clinical pharmacokinetics of alprazolam: Therapeutic implications. Clin Pharmacokinet 24:453-471.
8. Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI (1996): Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: In vitro and in vivo studies. J Clin Pharmacol 36:792-798.
9. Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH (1995): Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 15:399-408.
10. Harvey AT, Preskorn SH (1996): Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 16:273-285.
11. Holliday SM, Benfield P (1995): Venlafaxine: A review of its pharmacology and therapeutic potential in depression. Drugs 49:280-294.
12. Ketter TA, Flockhart DA, Post RM, et al (1995): The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 15:387-398.
13. Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF (1988): The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 43:412-419.
14. Otton SV, Ball SE, Cheung SW, Inava T, Rudolph RL, Sellers EM (1996): Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 41:149-156.
15. Perucca E, Gatti G, Cipolla G, et al (1994): Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 56:471-476.
16. Schmider J, Greenblatt DJ, von Moltke LL, Shader RI (1996): Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: Implications for diazepam disposition in humans. J Clin Psychopharmacol 16:267-272.
17. Troy SM, Lucki I, Peirgeis AA, Parker VD, Klockowski PM, Chiang ST (1995a): Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. J Clin Pharmacol 35:410-419.
18. Troy SM, Parker VD, Fruncillo RJ, Chiang ST (1995b): The pharmacokinetics of venlafaxine when given in a twice-daily regimen. J Clin Pharmacol 35:404-409.
19. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI (1994): Inhibitors of alprazolam metabolism in vitro: Effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 38:23-31.
20. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI (1995a): Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 15:125-131.
21. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI (1995b): Metabolism of drugs by cytochrome P450-3A isoforms: Implications for drug interactions in psychopharmacology. Clin Pharmacokinet 29 (suppl 1):33-43.
22. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI (1996a): Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 16:104-112.
23. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI (1996b): Nefazodone in vitro: Metabolic conversions, and inhibition of P450-3A isoforms. Clin Pharmacol Ther 59: 176.
24. Wright CE, Lasher-Sisson TA, Steenwyk RC, Swanson CN (1992): A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 12:103-106.